Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBITDA (2016 - 2025)

Historic EBITDA for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $54.9 million.

  • Ligand Pharmaceuticals' EBITDA rose 164772.51% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 20731.92%. This contributed to the annual value of -$22.6 million for FY2024, which is 28929.83% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' EBITDA is $54.9 million, which was up 164772.51% from $8.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year EBITDA high stood at $54.9 million for Q3 2025, and its period low was -$36.2 million during Q1 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' median EBITDA value was $3.1 million (recorded in 2024), while the average stood at $6.5 million.
  • The largest annual percentage gain for Ligand Pharmaceuticals' EBITDA in the last 5 years was 164772.51% (2025), contrasted with its biggest fall of 131204.82% (2025).
  • Ligand Pharmaceuticals' EBITDA (Quarter) stood at $37.7 million in 2021, then plummeted by 153.33% to -$20.1 million in 2022, then skyrocketed by 83.29% to -$3.4 million in 2023, then tumbled by 186.99% to -$9.6 million in 2024, then skyrocketed by 670.0% to $54.9 million in 2025.
  • Its EBITDA was $54.9 million in Q3 2025, compared to $8.4 million in Q2 2025 and -$36.2 million in Q1 2025.